A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia. Issue 3 (20th July 2022)

• Record Type: Journal Article
• Authors: Zhang, Hao; Meng, Guoyu
• Is Part Of: Blood science. Volume 4:Issue 3(2022)
• Page Start: 161
• Page End: 163
• Publication Date: 2022-07-20
• Subjects: B-ALL -- DUX4/IGH fusion -- MEF2D fusion -- Targeted therapy -- ZNF384 fusion; Hematology -- Periodicals; Blood -- Periodicals; Hematology; Blood; Hematology; Blood; Electronic journals; Periodicals; 616.15005
• DOI: 10.1097/BS9.0000000000000126
• Languages: English
• ISSNs: 2543-6368

Abstract

Abstract : B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs.